Renato Geralde
Family Medicine · San Antonio, TXNPI 1801894944
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,463 and has fallen 98.6% since, to $35 in 2024.
Across 195 payments — averaging $14.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$479
- Amgen$376
- AstraZeneca$296
- Novo Nordisk$281
- Lilly USA, LLC$243
- Johnson & Johnson$183
- plus $884 from 24 others
What the payments were for
- Food & beverage$2,63396%
- Education$1084%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $479 |
| Amgen(2 entities) | 26 | $376 |
| AstraZeneca | 16 | $296 |
| Novo Nordisk | 23 | $281 |
| Lilly USA, LLC | 29 | $243 |
| Johnson & Johnson | 10 | $183 |
| Akebia Therapeutics Inc | 4 | $80 |
| Gilead | 4 | $77 |
| GSK | 5 | $72 |
| Teva Pharmaceuticals USA, Inc. | 5 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Antares Pharma, Inc. | 4 | $56 |
| Nalpropion Pharmaceuticals LLC | 4 | $51 |
| Eisai Inc. | 3 | $41 |
| Aytu Biopharma, Inc. | 2 | $40 |
| Daiichi Sankyo Inc. | 3 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $36 |
| Abbott | 2 | $35 |
| Shire North American Group Inc | 2 | $26 |
| Merck | 2 | $23 |
| Roche Diagnostics Corporation | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Adlon Therapeutics L.p. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Acclarent, Inc | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
| Strongbridge US Inc. | 1 | $13 |
| Neuronetics, Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
How this compares
$2,741 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 34 | $735 |
| Desloratadine | 14 | $297 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $153 |
Paid to pharmacies, not to this prescriber.
Other family medicine in San Antonio
- Aaron KingSan Antonio$1.1M
- Solomon PaleySan Antonio$136K
- Sarah SamreenSan Antonio$133K
- Melissa WalkerSan Antonio$53K
- Paul SaenzSan Antonio$50K
- Carlos CamposNew Braunfels$1.5M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.